Trajan tips for business sustainability at AusMedtech 2016
Trajan Scientific and Medical (Trajan) Chief Executive Officer Stephen Tomisich, delivered the opening plenary at AusMedtech 2016 in Adelaide from 10 - 11 May, discussing how to grow and sustain scientific and medical device companies.
Mr Tomisich's address covered three key pillars to Trajan's business sustainability; foundation, activity, and risk mitigation.
View the full plenary video below, or on Trajan's YouTube channel.
More information
www.ausmedtech.com.au
Media contact information
Tel: +44 (0) 1244 403 100
media@trajanscimed.com
 Chief Executive Officer Stephen Tomisich, delivered the opening plenary at AusMedtech 2016 in Adelaide from 10 - 11 May, discussing how to grow and sustain scientific and medical device companies.
M...&media=//cdn.shopify.com/s/files/1/0767/9441/articles/AusMedtech2016StephenTomisich_600x.jpg?v=1463591878){kind=link}
Also in News
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
European patent for Trajan’s hemaPEN
US FDA listing of Trajan’s hemaPEN blood microsampling device
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.